Signos raises a $20.0M Series C round

Signos makes an FDA-cleared, over-the-counter continuous glucose monitoring app that turns biosensor data into personalized insights for weight management. The California-based company pairs Dexcom CGM hardware with an AI engine that helps non-diabetic users link food, activity, and metabolic response, and is sold direct-to-consumer through Dexcom's Stelo channel.